Synairgen Stock Soars 420% On Promise Of Inhaled COVID-19 Drug

Small Study Excites Investors

Preliminary results show that hospitalized coronavirus patients who received Synairgen's inhaled interferon beta product had a 79% lower risk of developing severe disease compared with placebo.

Covid19_Hospital_Room
Synairgen Drug Shows Potential For Hospitalized COVID-19 Patients • Source: Shutterstock

Small UK biotech Synairgen plc has announced some big news on its inhaled interferon beta candidate, SNG001, which significantly reduced the risk of severe disease in hospitalized patients with COVID-19, sending the firm's shares through the roof.

Southampton-based Synairgen has unveiled preliminary data from a study that recruited 101 patients from nine specialist hospital sites in the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip